FDA approves Johnson & Johnson’s nasal spray for depression

FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
US FDA approves J&J's ketamine-based therapy to treat depression
The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with major depressive disorder, the company said on Tuesday. The approval paves the way for use of Spravato in patients whose disease has stopped responding to at least two oral anti-depressants.
FDA approves first nasal spray for major depression disorder
The U.S. Food and Drug Administration on Tuesday approved the first nasal spray that will help with treating major depressive disorder.
FDA approves nasal spray drug to treat depression
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first and only monoth
Johnson & Johnson Gets FDA OK For Spravato as Monotherapy
Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression. J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.
What's the Connection Between Weight & Depression?
Part of you is concerned — after all, you know depression can be serious — but on the other hand, can’t weight loss be a good ...
Blue Monday isn’t real, but seasonal depression affects millions of people. There are ways to treat it
Blue Monday originated from a publicity stunt, but seasonal affective disorder is a real affliction that affects millions of ...
Drawing a line from the gut microbiome to inflammation and depression
It's become increasingly clear that the gut microbiome can affect human health, including mental health. Which bacterial ...
New Atlas6d
Depression breakthrough: Almost 300 previously unknown genes identified
We've never been closer to accurately assessing whether an individual is more susceptible to developing major depressive ...
Psychology Today3d
New Strategies for Treatment-Resistant Depression
Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...
France has the highest levels of depression in Europe. How does it compare with other countries?
A new report studied depression levels across Europe and in older and younger individuals, with the outlook for France ...
Inauguration Day in photos, the allure of coffee shops, how to handle seasonal depression: Catch up on the day’s stories
Inauguration Day in photos, the allure of coffee shops, how to handle seasonal depression: Catch up on the day’s stories ...
EastEnders’ Phil Mitchell attempts suicide as depression spirals in harrowing new mental health storyline
EASTENDERS’ Phil Mitchell battles with his mental health in a harrowing new storyline as depression spirals and he attempts ...